Blog Post

News and events
1 MIN READ

CDK Inhibitors approved by PBAC but cost is still an issue 20 April 2018

Giovanna_BCNA's avatar
7 years ago

CDK Inhibitors approved by Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue

See the link below for further information
https://www.bcna.org.au/news/2018/04/cdk-inhibitors-approved-by-pbac-but-costs-still-an-issue/

Published 7 years ago
Version 1.0
Related Content
Hi all - I have been treated for hormone positive stage 2 early breast cancer (grade 2/3) - lymph nodes were negative. I am on zoladex, exemestane and zoledronic acid. I am not on a CDK4/6 inhibitor. ...
6 months ago
Hi Everyone I'm 50 years old, I was diagnosed with stage 1breast cancer in late November last year. Early December 2022 I had surgery and removed a 18mm & 4.7mm cancerous tumors. The tumors were gra...
2 years ago